Bladder cancer: Clinical and pathological profile

Scandinavian Journal of Urology and Nephrology

Volumn 42, Issue SUPPL.218, 2008, Pages 95-109

  Lopez Beltran, Antonio ^a  

^a Universidad de Cordoba   (Spain)

Author keywords

Bladder cancer; Grade; Pathology; Stage

Indexed keywords

ANAMNESIS; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; CONFERENCE PAPER; DYSPLASIA; HEMATURIA; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; PAPILLARY CARCINOMA; PAPILLOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR; TUMOR GROWTH; WORLD HEALTH ORGANIZATION; BLADDER TUMOR; CLASSIFICATION; DISEASE COURSE; HYPERPLASIA; PATHOLOGY; REVIEW; UROTHELIUM;

DISEASE PROGRESSION; HUMANS; HYPERPLASIA; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 52949091975     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/03008880802325226     Document Type: Conference Paper

References (100)

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(Suppl 6A):4-34.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
3. Lopez-Beltran A, Montironi R. Non-invasive urothelial neoplasms: according to the most recent WHO classification. Eur Urol 2004;46:170-6.
4. Eble JN, Sauter G, Epstein JI, Sesterhenn IAE. World Health Organization classification of tumours: pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004.
5. Sauter G, Algaba F, Amin MB, Busch C, Cheville J, Gasser T, et al. Non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization classification of tumors: pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004.
6. Lopez-Beltran A, Sauter G, Gasser T, Hartmann A, Schmitz-Dräger BJ, Helpap B, et al. Urothelial tumors: infiltrating urothelial carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. World Health Organization classification of tumors: pathology and genetics of tumors of the urinary system and male genital organs. Lyon: IARC Press; 2004.
7. Montironi R, Lopez-Beltran A. The 2004 WHO classification of bladder tumors: a summary and commentary. Int J Surg Pathol 2005;13:143-53.
8. Reuter VE. The pathology of bladder cancer. Urology 2006;67(3 Suppl 1):11-7.
9. Pavone-Macaluso M, Lopez-Beltran A, Aragona F, Bassi P, Fitzpatrick JM. The pathology of bladder cancer: an update on selected issues. BJU Int 2006;98:1161-5.
10. Kretschmer HL. Hematuria: a clinical study based on 933 consecutive cases. Surg Gynecol Obstet 1925;40:683-8.
11. Varkarakis MJ, Gaeta J, Moore RH, Murphy GP. Superficial bladder tumor: aspects of clinical progression. Urology 1974;4:414-20.
12. Lee LW, Davis E Jr. Gross urinary hemorrhage: a symptom, not a disease. JAMA 1953;153:782-4.
13. Mohr DN, Offord KP, Owen RA, Melton LJ III. Asymptomatic microhematuria and urologic disease: a populationbased study. JAMA 1986;256:224-9.
14. Golin AL, Howard RS. Asymptomatic microscopic hematuria. J Urol 1980;124:389-91.
15. Malmström PU. Time to abandon testing for microscopic haematuria in adults? BMJ 2003;326:813-5.
16. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L. Morphological diagnosis of urothelial neoplasms. J Clin Pathol 2008;61:3-10.
17. Höglund M. On the origin of syn- and metachronous urothelial carcinomas. Eur Urol 2007;51:1185-93.
18. Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J Clin 1998;48:269-84.
19. Kaye KW, Lange PH. Mode of presentation of invasive bladder cancer: reassessment of the problem. J Urol 1982;128:31-3.
20. Malmstrom PU, Buch C, Norlen BJ. Recurrence, progression, and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand J Urol Nephrol 1987;21:185-95.
21. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-5.
22. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89.
23. Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol 1995;153:1823-6.
24. Kakizoe T. Development and progression of urothelial carcinoma. Cancer Sci 2006;97:821-8.
25. Jimenez RE, Gheiler E, Oskanian P, Tiguert R, Sakr W, Wood DP Jr, et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 2000;24:980-7.
26. Habuchi T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int J Urol 2005;12:709-16.
27. Denzinger S, Mohren K, Knuechel R, Wild PJ, Burger M, Wieland WF, et al. Improved clonality analysis of multifocal bladder tumors by combination of histopathologic organ mapping, loss of heterozygosity, fluorescence in situ hybridization, and p53 analyses. Hum Pathol 2006;37:143-51.
28. Jones TD, Wang M, Eble JN, MacLennan GT, Lopez-Beltran A, Zhang S, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11:6512-9.
29. Epstein JI, Amin MB, Reuter VR, Mostofi FK, Bladder Consensus Conference Committee. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22:1435-48.
30. Montironi R, Lopez-Beltran A, Mazzuchelli R, Bostwick DG. Classification and grading of the non-invasive bladder neoplasms: recent advances and controversies. J Clin Pathol 2003;56:91-5.
31. Lopez-Beltran A, Cheng L, Andersson L, Brausi M, de Matteis A, Montironi R, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 2002;440:3-11.
32. Hartmann A, Moser K, Kriegmair M, Hofstetter A, Hofstaedter F, Knuechel R. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999;154:721-7.
33. Taylor DC, Bhagavan BS, Larsen MP, Cox JA, Epstein JI. Papillary urothelial hyperplasia. A precursor to papillary neoplasms. Am J Surg Pathol 1996;20:1481-8.
34. Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol 1999;23:443-7.
35. Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002;62:809-18.
36. Harnden P, Eardley I, Joyce AD, Southgate J. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996;78:870-87.
37. Cheng L, Cheville JC, Leibovich BC, Weaver AL, Egan KS, Spotts BE, et al. Survival of patients with carcinoma in situ of the urinary bladder. Cancer 1999;85:2469-74.
38. Lopez-Beltran A, Luque RJ, Moreno A, Bollito E, Carmona E, Montironi R. The pagetoid variant of bladder urothelial carcinoma in situ. A clinicopathological study of 11 cases. Virchows Arch 2002;441:148-53.
39. McKenney JK, Gomez JA, Desai S, Lee MW, Amin MB. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 2001;25:356-62.
40. Farrow GM, Utz DC. Observations on microinvasive transitional cell carcinoma of the urinary bladder. Clin Oncol 1982;1:609-14.
41. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. Geneva: World Health Organization; 1973.
42. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodr? guez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000;163:73-8.
43. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
44. Jakse G, Loidl W, Seeber G, Hofstädter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 1987;137:39-43.
45. Lopez-Beltrana A, Bassi PF, Pavone-Macaluso M, Montironi R. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. Eur Urol 2004;45:257-66.
46. Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch 2002;441:109-16.
47. Cheng L, Darson M, Cheville JC, Neumann RM, Zincke H, Nehra A, et al. Urothelial papilloma of the bladder. Clinical and biologic implications. Cancer 1999;86:2098-101.
48. McKenney JK, Amin MB, Young RH. Urothelial (transitional cell) papilloma of the urinary bladder: a clinicopathologic study of 26 cases. Mod Pathol 2003;16:623-9.
49. Cheng L, Neumann RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications. Cancer 1999;86:2102-8.
50. Alsheikh A, Mohamedali Z, Jones E, Masterson J, Gilks CB. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/International Society of Urologic Pathology. Mod Pathol 2001;14:267-72.
51. Oosterlinck W, Solsona E, Akaza H, Busch C, Goebell PJ, Malmstrom PU, et al. Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology 2005;66(6 Suppl 1):75-8.
52. Jones TD, Cheng L. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol 2006;175:1995-2003.
53. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 2000;13:1315-23.
54. Fujii Y, Kawakami S, Koga F, Nemoto T, Kihara K. Longterm outcome of bladder papillary urothelial neoplasms of low malignant potential. BJU Int 2003;92:559-62.
55. Holmang S, Andius P, Hedelin H, Wester K, Busch C, Johansson SL. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165:1124-8.
56. Holmang S, Johansson SL. Stage Ta-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol 2002;167:1634-7.
57. Murphy WM, Takezawa K, Maruniak NA. Interobserver discrepancy using the 1998 World Health Organization/International Society of Urologic Pathology classification of urothelial neoplasms: practical choices for patient care. J Urol 2003;168:968-72.
58. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Pauwels RP, Newling DW, ten Kate F. Histological grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading systems. J Clin Pathol 2002;55:900-5.
59. Pich A, Chiusa L, Formiconi A, Galliano D, Bortolin P, Navone R. Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder. Am J Surg Pathol 2001;25:1528-33.
60. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002;60:315-9.
61. van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002;198:245-51.
62. Sung MT, Maclennan GT, Lopez-Beltran A, Montironi R, Cheng L. Natural history of urothelial inverted papilloma. Cancer 2006;107:2622-7.
63. Sung MT, Eble JN, Wang M, Tan PH, Lopez-Beltran A, Cheng L. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol 2006;19:1289-94.
64. Jones TD, Zhang S, Lopez-Beltran A, Eble JN, Sung MT, MacLennan GT, et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol 2007;31:1861-7.
65. Barbisan F, Santinelli A, Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, et al. Strong immunohistochemical expression of fibroblast growth factor receptor 3, superficial staining pattern of cytokeratin 20, and low proliferative activity define those papillary urothelial neoplasms of low malignant potential that do not recur. Cancer 2008;112:636-44.
66. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. AJCC cancer staging manual. New York: Springer; 2002.
67. Cheng L, Weaver AL, Leibovich BC, Ramnani DM, Neumann RM, Sherer BG, et al. Predicting the survival of bladder carcinoma patients treated with radical cystectomy. Cancer 2000;88:2326-32.
68. Dalbagni G, Herr HW, Reuter VE. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 2002;60:822-4.
69. Esrig D, Freeman JA, Stein JP, Skinner DG. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol 1997;15:154-60.
70. Bochner BH, Kattan MW, Vora KC, International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J Clin Oncol 2006;24:3967-72.
71. Bassi P, Ferrante GD, Piazza N, Spinadin R, Carando R, Pappagallo G, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 1999;161:1494-7.
72. Miladi M, Peyromaure M, Zerbib M, Saighi D, Debre B. The value of a second transurethral resection in evaluating patients with bladder tumors. Eur Urol 2003;43:241-5.
73. Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, et al. Bladder Cancer Research Consortium. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. J Urol 2006;175:1645-9.
74. Bol M, Baak J, Buhr-Wildhagen S. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003;169:1291-4.
75. Tosoni I, Wagner U, Sauter G, Egloff M, Knönagel H, Alund G, et al. Clinical significance of interobserver differences in the staging and grading of superficial bladder cancer. BJU Int 2000;85:48-53.
76. Van der Meijden A, Sylvester R, Collette L, Bono A, ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 2000;164:1533-7.
77. Cheng L, Neumann RM, Weaver AL, Spotts B, Bostwick DG. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999;17:3182-7.
78. Lopez-Beltran A, Cheng L. Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance. Pathology 2003;35:484-91.
79. Jimenez RE, Keany TE, Hardy HT, Amin MB. pT1 Urothelial carcinoma of the bladder: criteria for diagnosis, pitfalls, and clinical implications. Adv Anat Pathol 2000;7:13-25.
80. Angulo JC, Lopez JI, Grignon DJ, Sanchez-Chapado M. Muscularis mucosae differentiates two populations with different prognosis in stage T1 bladder cancer. Urology 1995;45:47.
81. Hasui Y, Osada Y, Kitada S, Nishi S. Significance of invasion to the muscularis mucosae on the progression of superficial bladder cancer. Urology 1994;43:782-6.
82. Holmang S, Hedelin H, Anderstrom C, Holmberg E, Johansson SL. The importance of the depth of invasion in stage T1 bladder carcinoma bladder carcinoma: a prospective cohort study. J Urol 1997;157:800-4.
83. Platz CE, Cohen MB, Jones MP, Olson DB, Lynch CF. Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol 1996;11:1035-9.
84. Ro JY, Ayala AG, el-Naggar A. Muscularis mucosa of urinary bladder. Importance for staging and treatment. Am J Surg Pathol 1987;11:668-73.
85. Sozen S, Akbal C, Sokmensuer C, Ekici S, Ozen H. Microstaging of pT1 transitional cell carcinoma of the bladder. Does it really differentiate two populations with different prognoses? (pT1 subcategory). Urol Int 2002;69:200-6.
86. Younes M, Sussman J, True LD. The usefulness of the level of the muscularis mucosae in the staging of invasive transitional cell carcinoma of the urinary bladder. Cancer 1990;66:543-8.
87. Harry W, Herr S, Donat M, Reuter VE. Management of low grade papillary bladder tumors. J Urol 2007;178:1201-5.
88. Tokgoz H, Turkolmez K, Resorlu B, Kose K, Tulunay O, Beduk Y. Pathological staging of muscle invasive bladder cancer. Is substaging of pT2 tumors really necessary? Int Braz J Urol 2007;33:777-84.
89. Bayraktar Z, Gorbuz G, Ihsan AT, Sevin G. Staging error in the bladder tumor: the correlation between stage of TUR and cystectomy. Int J Urol Nephrol 2002;33:627-9.
90. Pollack A, Zagars GK, Cole CJ, Dinney CP, Swanson DA, Grossman HB. Significance of downstaging in muscleinvasive bladder cancer treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 1997;37:41-9.
91. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, et al. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol 2004;171(2 Pt 1):640-5.
92. Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, et al. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer 2003;98:955-61.
93. Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol 2006;37:726-34.
94. Esrig D, Freeman JA, Elmajian DA, Stein JP, Chen SC, Groshen S, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 1996;156:1071-6.
95. Pagano F, Bassi P, Ferrante GL, Piazza N, Abatangelo G, Pappagallo GL, et al. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J Urol 1996;155:244-7.
96. Leissner J, Koeppen C, Wolf HK. Prognostic significance of vascular and perineural invasion in urothelial bladder cancer treated with radical cystectomy. J Urol 2003;169:955-60.
97. Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol 2005;23:6533-9.
98. Reuter VE. Lymphovascular invasion as an independent predictor of recurrence and survival in node-negative bladder cancer remains to be proven. J Clin Oncol 2005;23:6450-1.
99. Honma I, Masumori N, Sato E, Maeda T, Hirobe M, Kitamura H, Takahashi A, et al. Removal of more lymph nodes may provide better outcome, as well as more accurate pathologic findings, in patients with bladder cancer - analysis of role of pelvic lymph node dissection. Urology 2006;68:543-8.
100. Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney C, et al. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer 2006;107:1491-5.